EA200970042A1 - Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение - Google Patents

Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение

Info

Publication number
EA200970042A1
EA200970042A1 EA200970042A EA200970042A EA200970042A1 EA 200970042 A1 EA200970042 A1 EA 200970042A1 EA 200970042 A EA200970042 A EA 200970042A EA 200970042 A EA200970042 A EA 200970042A EA 200970042 A1 EA200970042 A1 EA 200970042A1
Authority
EA
Eurasian Patent Office
Prior art keywords
basis
compositions
hemzitabin
amida
development
Prior art date
Application number
EA200970042A
Other languages
English (en)
Other versions
EA014909B1 (ru
Inventor
Александр Евгеньевич Облезов
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970042A1 publication Critical patent/EA200970042A1/ru
Publication of EA014909B1 publication Critical patent/EA014909B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к новым кристаллическим формам амидного пролекарства на основе гемцитабина, композициям на их основе и способам их применения.
EA200970042A 2006-06-21 2007-06-20 Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение EA014909B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81550806P 2006-06-21 2006-06-21
US81540706P 2006-06-21 2006-06-21
PCT/US2007/071613 WO2007149891A2 (en) 2006-06-21 2007-06-20 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof

Publications (2)

Publication Number Publication Date
EA200970042A1 true EA200970042A1 (ru) 2009-04-28
EA014909B1 EA014909B1 (ru) 2011-02-28

Family

ID=38670971

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970042A EA014909B1 (ru) 2006-06-21 2007-06-20 Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение

Country Status (11)

Country Link
US (1) US8114854B2 (ru)
EP (1) EP2043653B1 (ru)
JP (1) JP5225271B2 (ru)
KR (1) KR101108407B1 (ru)
CN (1) CN101448504B (ru)
AU (1) AU2007261002B2 (ru)
CA (1) CA2652633C (ru)
EA (1) EA014909B1 (ru)
ES (1) ES2446092T3 (ru)
MX (1) MX2009000198A (ru)
WO (1) WO2007149891A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110025178A (ko) * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
CN102216314A (zh) * 2008-06-12 2011-10-12 台湾神隆股份有限公司 吉西他滨碱的结晶多晶型物
CN101525361B (zh) * 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
KR20150082606A (ko) 2012-11-13 2015-07-15 보옌 테라퓨틱스, 인크. 겜시타빈 전구약물 및 그의 용도
RU2681939C2 (ru) 2013-10-29 2019-03-14 Оцука Фармасьютикал Ко., Лтд. Путь синтезирования 2'-дезокси-2'2'-дифтортетрагидроуридинов

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4352115B2 (ja) * 1997-01-24 2009-10-28 クラヴィス・ファルマ・アーエスアー ゲムシタビン誘導体
AU2003291726A1 (en) 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
EP1831237B1 (en) 2004-12-17 2008-08-20 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof

Also Published As

Publication number Publication date
ES2446092T3 (es) 2014-03-06
AU2007261002A1 (en) 2007-12-27
CA2652633C (en) 2014-03-25
CA2652633A1 (en) 2007-12-27
CN101448504B (zh) 2012-04-11
US20090203640A1 (en) 2009-08-13
JP5225271B2 (ja) 2013-07-03
EP2043653B1 (en) 2013-12-25
EA014909B1 (ru) 2011-02-28
MX2009000198A (es) 2009-01-22
WO2007149891A2 (en) 2007-12-27
CN101448504A (zh) 2009-06-03
JP2009541344A (ja) 2009-11-26
WO2007149891A3 (en) 2008-02-14
AU2007261002B2 (en) 2012-03-08
KR101108407B1 (ko) 2012-01-30
US8114854B2 (en) 2012-02-14
KR20090033447A (ko) 2009-04-03
EP2043653A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
EA200701300A1 (ru) Амидное пролекарство гемцитабина, композиции на его основе и его применение
CR11776A (es) Inhibidores de bace
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
MY148253A (en) Azaadamantane derivatives and methods of use
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
ECSP10010722A (es) Compuestos orgánicos
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
CR20110204A (es) Moleculas de anticuerpo mejoradas
EA200970156A1 (ru) Пиридизиноновые производные
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
HN2006016313A (es) Derivados de amida sustituida y metodos de uso
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
CR20140135A (es) Nuevos derivados de aril-quinolina
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
EA201001243A1 (ru) Кристаллические формы n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамида и способы их получения
EA200801676A1 (ru) Комбинация производных триазина и сенсибилизаторов инсулина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ RU